Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Battelle User Interface Design for Generic vs. RLD Combination Products

Award Number: U01FD007359
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2021
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Battelle User Interface Design for Generic vs. RLD Combination Products - PROJECT SUMMARY/ABSTRACT In 2019, the Food and Drug Administration issued approvals for generic combination products including the Fluticasone and Salmeterol Inhalation Powder and the Naloxone Nasal Spray. Generic devices like these have the potential to cause harm to a patient or user if the user interface is not carefully evaluated to ensure a generic product’s user interface is substitutable when compared to that of its reference listed drug (RLD). Understanding the factors that could impact safe and effective use is critical when evaluating a generic combination product as there is a higher likelihood for use error resulting from a user’s pre- existing mental model, based on use experience with the RLD. Additionally, the reliance of an abbreviated new drug application (ANDA) on FDA’s findings that the RLD is safe and effective relies on the premise that there are no user interface differences that would undermine the therapeutic equivalence of the generic to the RLD. Battelle applies a risk-based human-centric design (HCD) approach to medical device development that predates FDA guidance on the subject. Battelle will modify this approach to develop methods for effectively evaluating a generic device against an RLD. Battelle will collaborate with the federal research team to accomplish the following two (2) aims: Aim 1: Develop enhanced methods for threshold analysis and categorization of user interface differences. Battelle will leverage extensive device development and human factors expertise to collaborate with the FDA to develop a risk-based approach to support the categorization of differences in the design of a user interface. Battelle will select specific representative combination products for analysis. Battelle will implement or modify their existing usability engineering (UE) methods to perform use risk analyses of key elements of the selected devices to support the appropriate categorization of the user interfaces. Aim 2: Establish effective methods for assessing “other” design differences.” Battelle will utilize their in- house expertise to develop custom methods for evaluation and data collection. Combined with Battelle’s experience developing creative modeling solutions for a variety of human tissue types, Battelle will produce methods that will accurately assess whether other differences in the user interface introduce a risk that might impact the clinical effect or safety profile of the generic drug-device combination product as compared to the RLD. The evaluation methods developed by Battelle and the federal research team will be applicable for all stakeholders engaged in the development of generic drug-device combination products. This effort will result in an improved set of tools for evaluating how differences in the user interface of a proposed generic combination product as compared to the RLD may impact the overall use of a product.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2022	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	000	2	8/13/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	000	2	4/29/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $99,430 )
2023	2023	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	001	2	1/10/2023	SUPPLEMENT FOR EXPANSION	$99,430
2023	2022	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	002	2	3/22/2023	NON-COMPETING CONTINUATION	$0
2023	2022	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	003	2	9/18/2023	NON-COMPETING CONTINUATION	$0
2023	2021	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	000	1	12/19/2022	NEW	$0
														Subtotal = $99,430

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2022	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	001	2	8/31/2022	NON-COMPETING CONTINUATION	$0
2022	2021	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	000	1	6/16/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $199,995 )
2021	2021	BATTELLE MEMORIAL INSTITUTE	505 KING AVE	COLUMBUS	OH	43201	FRANKLIN	USA	Food and Drug Administration Research	000	1	7/20/2021	NEW	$199,995
														Subtotal = $199,995

Grand Total All Awards = $299,425

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Battelle User Interface Design for Generic vs. RLD Combination Products

Award Number: U01FD007359

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2021

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer